Interaction between OCT1 and LPIN1 polymorphisms and response to pioglitazone-metformin tablets in patients with polycystic ovary syndrome

Chin Med J (Engl). 2023 Jul 20;136(14):1756-1758. doi: 10.1097/CM9.0000000000002322. Epub 2023 May 26.

Authors

Haixia Zeng¹, Yanting Huang², Dengke Liu¹, Tianqin Xie¹, Zheng Chen¹, Qiulan Huang¹, Xiaojun Zhou³, Xiaoyang Lai¹, Jianping Liu¹

Affiliations

¹ Department of Endocrinology, Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China.
² Department of Endocrinology, Xiangyang First People's Hospital, Xiangyang, Hubei 441099, China.
³ School of Public Health, Nanchang University, School of Public Health, Nanchang University, Nanchang, Jiangxi 330031, China.

No abstract available

Publication types

Letter

MeSH terms

Female
Humans
Hypoglycemic Agents / therapeutic use
Insulin Resistance*
Metformin* / therapeutic use
Phosphatidate Phosphatase
Pioglitazone / therapeutic use
Polycystic Ovary Syndrome* / drug therapy
Polycystic Ovary Syndrome* / genetics

Substances

Hypoglycemic Agents
LPIN1 protein, human
Metformin
Phosphatidate Phosphatase
Pioglitazone